全文获取类型
| 收费全文 | 4646309篇 |
| 免费 | 339275篇 |
| 国内免费 | 12946篇 |
专业分类
| 耳鼻咽喉 | 65525篇 |
| 儿科学 | 149417篇 |
| 妇产科学 | 127095篇 |
| 基础医学 | 651322篇 |
| 口腔科学 | 135020篇 |
| 临床医学 | 437678篇 |
| 内科学 | 887090篇 |
| 皮肤病学 | 102187篇 |
| 神经病学 | 385447篇 |
| 特种医学 | 177624篇 |
| 外国民族医学 | 1646篇 |
| 外科学 | 684531篇 |
| 综合类 | 107484篇 |
| 现状与发展 | 7篇 |
| 一般理论 | 2048篇 |
| 预防医学 | 381893篇 |
| 眼科学 | 108957篇 |
| 药学 | 343749篇 |
| 16篇 | |
| 中国医学 | 9619篇 |
| 肿瘤学 | 240175篇 |
出版年
| 2018年 | 50567篇 |
| 2017年 | 38600篇 |
| 2016年 | 43688篇 |
| 2015年 | 49371篇 |
| 2014年 | 69468篇 |
| 2013年 | 106835篇 |
| 2012年 | 142387篇 |
| 2011年 | 151457篇 |
| 2010年 | 90710篇 |
| 2009年 | 85797篇 |
| 2008年 | 141489篇 |
| 2007年 | 150178篇 |
| 2006年 | 151925篇 |
| 2005年 | 146988篇 |
| 2004年 | 141113篇 |
| 2003年 | 135934篇 |
| 2002年 | 132195篇 |
| 2001年 | 205241篇 |
| 2000年 | 211328篇 |
| 1999年 | 179570篇 |
| 1998年 | 54784篇 |
| 1997年 | 48571篇 |
| 1996年 | 47831篇 |
| 1995年 | 46266篇 |
| 1994年 | 43061篇 |
| 1993年 | 40503篇 |
| 1992年 | 143480篇 |
| 1991年 | 139601篇 |
| 1990年 | 135286篇 |
| 1989年 | 130541篇 |
| 1988年 | 120820篇 |
| 1987年 | 119117篇 |
| 1986年 | 112911篇 |
| 1985年 | 108383篇 |
| 1984年 | 81909篇 |
| 1983年 | 70285篇 |
| 1982年 | 42458篇 |
| 1981年 | 38250篇 |
| 1979年 | 75823篇 |
| 1978年 | 53962篇 |
| 1977年 | 45583篇 |
| 1976年 | 43092篇 |
| 1975年 | 45518篇 |
| 1974年 | 55227篇 |
| 1973年 | 53143篇 |
| 1972年 | 49848篇 |
| 1971年 | 46428篇 |
| 1970年 | 43425篇 |
| 1969年 | 40893篇 |
| 1968年 | 37877篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
31.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献32.
Andrea Garatti Andrea Daprati Marzia Cottini Claudio F. Russo Margherita Dalla Tomba Giovanni Troise Antonio Salsano Francesco Santini Roberto Scrofani Francesca Nicolò Elisa Mikus Alberto Albertini Luca Di Marco Davide Pacini Marco Picichè Loris Salvador Guglielmo M. Actis Dato Paolo Centofanti Lorenzo Menicanti 《The Annals of thoracic surgery》2021,111(4):1242-1251
- Download : Download high-res image (165KB)
- Download : Download full-size image
33.
34.
35.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献36.
Optimizing glycemic control remains a shared challenge for clinicians and their patients with diabetes. Flash continuous glucose monitoring (CGM) provides immediate information about an individual’s current and projected glucose level, allowing users to respond promptly to mitigate or prevent pending hypoglycemia or hyperglycemia. Large randomized controlled trials (RCTs) have demonstrated the glycemic benefits of flash CGM use in both type 1 and type 2 diabetes. However, whereas RCTs are mostly focused on the efficacy of this technology in defined circumstances, real-world studies can assess its effectiveness in wider clinical settings. This review assesses the most recent real-world studies demonstrating the effectiveness of flash CGM use to improve clinical outcomes and health care resource utilization in populations with diabetes.During the past 5 years, increasing numbers of people with type 1 or type 2 diabetes have integrated continuous glucose monitoring (CGM) into their diabetes self-management regimens. Unlike traditional blood glucose meters, CGM systems provide immediate information about the concentration and the direction and rate of change of interstitial glucose. This information enables patients to intervene promptly to prevent or reduce acute hypoglycemia or hyperglycemia.Flash CGM is among the most recent CGM technologies. Currently, the FreeStyle Libre 14-day system (Abbott Diabetes Care) and FreeStyle Libre 2 are the only flash CGM systems available, and these systems are being adopted rapidly. Large randomized controlled trials (RCTs) have confirmed the glycemic benefits of flash CGM use in people with type 1 diabetes (1,2) and those with type 2 diabetes (3–6). However, because RCTs are mostly focused on measures of efficacy in defined circumstances, real-world studies can usefully assess the effectiveness of flash CGM in wider clinical settings.Although adoption of flash CGM continues to expand within endocrinology and diabetes specialty practices, primary care providers may be less familiar with this technology and how it can benefit patients with diabetes. This review assesses recent real-world studies demonstrating the impact of flash CGM use on clinical outcomes and health care resource utilization in both type 1 and type 2 diabetes populations. 相似文献
37.
38.
Though cerebrovascular complications of pregnancy remain relatively rare, they represent a potentially devastating event that necessitates prompt identification and treatment. Eighteen percent of strokes occurring in young women are linked to pregnancy. They occur mostly in the third trimester or during the post-partum period. Their biggest risk factors are hypertension, preeclampsia/eclampsia and migraine. Cerebrovascular events occurring during this period may involve specific pathophysiological processes that include embolic phenomena or endothelial dysfunction, but can also have common etiologies that are simply favored by the context of pregnancy. Thus, posterior encephalopathy and vasoconstriction cerebral syndrome are relatively frequently involved in cerebrovascular complications of pregnancy. Other very specific causes like amniotic fluid embolism or postpartum cardiomyopathy can also be responsible for such events. The management of stroke during pregnancy must be multidisciplinary and include a neurovascular expertise. Some conditions can lead to a long-life follow-up and modify the management of a future pregnancy. 相似文献
39.
40.
Emiliano A. Rodríguez-Caulo Ana Guijarro-Contreras Arantza Guzón Juan Otero-Forero María José Mataró Gemma Sánchez-Espín Carlos Porras José M. Villaescusa José María Melero-Tejedor Manuel Jiménez-Navarro 《Seminars in thoracic and cardiovascular surgery》2021,33(2):328-334
- Download : Download high-res image (200KB)
- Download : Download full-size image